Review Proposes Gut Microbiota-Ferroptosis Axis in PCOS and Potential TCM Role

A systematic review article explores the scientific rationale for a gut microbiota-ferroptosis axis in the pathophysiology of polycystic ovary syndrome (PCOS). The review proposes that gut microbiota dysbiosis may act as a potential upstream trigger, disrupting iron homeostasis and reducing antioxidant metabolites like short-chain fatty acids. This is theorized to exacerbate oxidative stress, induce ferroptosis in ovarian granulosa cells, and contribute to impaired follicular development and insulin resistance.

The review identifies Traditional Chinese Medicine (TCM) monomers and compounds, including berberine and quercetin, as having significant potential to regulate gut microbiota and inhibit ferroptosis. The authors suggest TCM may offer benefits as an adjunct or alternative to conventional PCOS therapies. No specific clinical trial data, effect sizes, or patient outcomes are reported to support this therapeutic potential.

Safety and tolerability data for TCM interventions in this context are not reported. Key limitations stem from the review's nature: it presents a theoretical perspective and explores mechanisms and application prospects rather than reporting new experimental or clinical trial results. It does not establish causation. The population, sample size, study setting, comparator, and follow-up duration are all not reported.

For clinical practice, this review highlights an area of active mechanistic research but provides no evidence for changing current management. The proposed axis and therapeutic role of TCM remain speculative and require rigorous clinical investigation.